key: cord-0983986-1t8e73u1 authors: Ramos, Laura; Carrillo-Palau, Marta; Alonso-Abreu, Inmaculada; Reygosa, Cristina; Hernández-Alvarez, Noemi; Amaral, Carla; Hernández, Anjara; Benítez-Zafra, Federica; Pérez-González, Fabiola; Quintana-Díaz, Haridian; Hernandez-Guerra, Manuel title: COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire date: 2022-05-21 journal: Gastroenterol Hepatol DOI: 10.1016/j.gastrohep.2022.05.009 sha: 108f4acf7630978c482eddb61f009f3ccf7110b3 doc_id: 983986 cord_uid: 1t8e73u1 Background: Vaccination against COVID19 prevents its severe forms and associated mortality and offers a promising action to control this pandemic. In September 2021, an additional dose of vaccine was approved in patients with immunosuppression including IBD patients on biologic agents. We evaluated the vaccination rate and additional dose willingness in this group of-at risk patients. Methods: A single-center, cross-sectional study was performed among IBD patients on biologic agents and eligible for an additional dose of the COVID19 vaccine. IBD clinical characteristics and type of vaccine and date of administration were checked in medical records. Acceptance was evaluated after telephone or face-to-face surveys in IBD patients. Results: Out of a total of 344 patients, 269 patients(46.1% male; mean age 47±16 years; Crohn’s disease 73.6%) were included. Only 15(5.6%) patients refused the COVID19 vaccine mainly (40%) for conviction (COVID19 pandemic denial). 33.3% would re-consider after discussing with their doctor and/or receiving information on the adverse effects of the vaccine. Previous to the additional dose, the COVID19 vaccination was present in 94.4% of patients(n=254). Adverse effects occurred in 53.9% of the cases, mainly pain in the arm(40%). Up to 94.1% of the patients agreed to an additional dose and 79.4% had already received the additional dose at the final time of the assessment. Conclusions: IBD patients on biological agents accept the vaccine as well as an additional dose if recommended. Physicians in charge of IBD units should provide information and confidence in the use of the vaccine in these IBD patients. Vaccination against COVID19 prevents its severe forms and associated mortality and offers a promising action to control this pandemic. In September 2021, an additional dose of vaccine was approved in patients with immunosuppression including IBD patients on biologic agents. We evaluated the vaccination rate and additional dose willingness in this group of-at risk patients. A single-center, cross-sectional study was performed among IBD patients on biologic agents and eligible for an additional dose of the COVID19 vaccine. IBD clinical characteristics and type of vaccine and date of administration were checked in medical records. Acceptance was evaluated after telephone or faceto-face surveys in IBD patients. Out of a total of 344 patients, 269 patients(46.1% male; mean age 47±16 years; Crohn's disease 73.6%) were included. Only 15(5.6%) patients refused the COVID19 vaccine mainly (40%) for conviction (COVID19 pandemic denial). 33.3% would re-consider after discussing with their doctor and/or receiving information on the adverse effects of the vaccine. Previous to the additional dose, the COVID19 vaccination was present in 94.4% of patients(n=254). Adverse effects occurred in 53.9% of the cases, mainly pain in the arm(40%). Up to 94.1% of the patients agreed to an additional dose and 79.4% had already received the additional dose at the final time of the assessment. de vacuna en pacientes con inmunosupresión, incluidos los pacientes con enfermedad inflamatoria intestinal (EII) que reciben agentes biológicos. En este estudio se evaluó la tasa de vacunación y la disposición de recibir la dosis adicional de vacuna en este grupo de pacientes de riesgo. Se realizó un estudio transversal unicéntrico con pacientes afectos de EII con tratamiento biológico y elegibles para una dosis adicional de la vacuna COVID19.Se evaluó la aceptación y los efectos adversos de la vacuna mediante encuesta telefónica o presencial y se recopiló en las historias clínicas las características de la EII, el tipo de vacuna recibida y la fecha de administración. De un total de 344 pacientes, 269 (46,1% hombres; edad media 47±16 años; enfermedad de crohn n=198) fueron incluidos. Sólo 15 (5,6%) pacientes rechazaron la vacuna frente al COVID19, 40% por convicción (negación de la pandemia COVID19). Antes de la dosis adicional, la vacuna COVID19 se había administrado en el 94,4% de los pacientes (n=254). En el 53,9% de los casos se presentaron efectos adversos, principalmente dolor en el brazo (40%).Hasta el 94,1% de los pacientes refería la aceptación de una dosis adicional de la vacuna y el 79,1% ya había recibido esta dosis adicional en el momento de la evaluación final. Los pacientes con EII que reciben agentes biológicos aceptan la vacuna frente al COVID19, así como una dosis adicional si se les recomienda. Los médicos responsables de las unidades de EII deben proporcionar información y confianza en el uso de la vacuna en estos pacientes. The design of effective vaccines against the SARS-CoV-2, induces an immune response developing high-affinity antibodies or effector T cells, prevents its severe forms and associated mortality, and offers a promising action to control the COVID-19 pandemic. Several vaccines against COVID-19 are already available and recommended in global immunization programs for the entire population over 5 years of age 1 . Vaccination is especially important in vulnerable cohorts, particularly those considered immunocompromised which include a subset of patients with IBD using biologic agents, small molecules, immunomodulators, and /or corticosteroids. Previous studies have shown that immunosuppressive drugs in IBD patients may reduce the effectiveness of some vaccines and therefore the vaccination protocol e.g. hepatitis B or influenza may be accelerated or the dose may be increased in these patients to adjust to this Acceptance and safety of vaccination and willingness of the additional dose were evaluated by a face-to-face or telephone survey after consent to participate in the study. IBD patients accepted to be included and completed the survey during the medical consultation or were contacted by phone and they were asked to participate in the study (giving verbal consent) and completed a telephonic survey in a period between 19 to October and 12th November 2021. We developed a short questionary (9-items) including 7 closed questions (Yes/No or pre-defined response) to reduce non-response rates. If the patients were hesitant or refused to be vaccinated they were asked about their reasons and whether there was any action to change their decision. The questionnaire is included in Appendix A. The side effects of the vaccine after the initial regimen (2 doses for Pfizer, Moderna, and Astra Zeneca and 1 dose of Jannsen) were described. The survey was conducted by a non-IBD staff member to avoid interference in the physicianpatient relationship with the assessment of the survey. The type of COVID-19 vaccine and date of administration was confirmed in medical records. If the patient had received the additional dose of vaccine it was also checked; the revision was carried out two separate times during the study ( at the end of November and December 2021). The infection for SARs-CoV-2 was also revised and when it occurs (before or after vaccination) and any complication related to the COVID-19 infection (hospital admission, need for ICU, or death). Out of a total of 344 patients, 269 patients received at least one vaccine dose and were included. We were not able to contact 72 patients and 3 refused to participate in the study. The description of demographic and clinical characteristics is shown in Table 1 ; 198 (73.6%) were Crohn´s disease patients, gender distribution was similar (51.8% female) with a mean age of 47±16 years. Among the 12 months before the vaccination assessment, up to 42.2% (n=113) of patients required a change in their usual medical treatment, 9.3% (n=25) patients were admitted to the hospital for IBD flares or complications, and 3% (n=8) required surgery for IBD during the pandemic. Only 15 (5.6%) patients had not been vaccinated at initial evaluation and when considering the reason: 26.7% for fear of the vaccine`s adverse effects, 33.3% for doubts about a "new-design" vaccine, and 40% for conviction (COVID19 pandemic denial). 46.7% of the cases would not change their opinion, but 33.3% would re-consider after discussing with their doctor and/or receiving information on the adverse effects of the vaccine. 13.3% did not want to evaluate these options (no answer) and 6.7% (n=1) would consider changing the decision after the call was received. In our study, the COVID-19 vaccination rate in group of patients with IBD using biological agents is very high (94.4%) and they accept to receive an additional dose of vaccine if it is recommended (94.1% of those previously vaccinated). In addition, the vaccine is safe with non-serious side effects in these IBD patients. Even though there were certain concerns that IBD patients may be at risk of suboptimal vaccine response, a prior study demonstrated that the incidence of COVID-19 in IBD patients after vaccination is very low, including patients on immunosuppressive agents, and is similar to non-IBD population 6 . In the present study we have evaluated the vaccination rate and the acceptance Remarkably, a collaborative study between the Spanish IBD Working Group (GETECCU) and the national patient association (ACCU Spain) showed that only 43% were willing to be vaccinated against COVID19 but without an increasing concern about vaccination since the pandemic or fear due to IBD treatments 9 . However, a multicenter survey performed in Germany showed that 58.5% of IBD patients planned to get COVID19 vaccination or had already been vaccinated and those without IBD treatment were less willing to get vaccinated 10 In IBD patients, we dispose of consensus guidelines for providing vaccines and obtaining immunization to ensure health care maintenance for patients with IBD 12 . A recent study using data from the US showed improving and higher immunization rates in IBD patients than the general population but still suboptimal with yearly influenza and pneumococcal vaccine uptake (48% and 75%, respectively) 13 . In Spain, adherence to the vaccination program was acceptable, raising a rate f 84.3% among IBD patients. However, the vaccination compliance was shown to be dependent on the type of treatment (decreased if not use of immunosuppressants) and adherence to IBD maintenance therapy. Concluded that optimization of patient information on the disease and emphasis on the need for adequate vaccination was necessary to improve adherence 14 . Related to the vaccine against COVID19, by January 2022, 90.8% of the population older than 12 years of age in Spain had received the complete vaccination regimen 1 . As we found in our study, not only the vaccination rate but also the acceptance rate of the additional dose was very high in these patients, rising to 74.6% in just 2 months of the vaccination campaign. The main limitation of the study is the reduced number of patients as a singlecenter study and represented a country with high vaccine acceptance and an acceptable rate of vaccination program adherence in IBD patients. In addition, we do not have data on patients who declined or could be enrolled in the study and who might have a differential adherence profile to COVID-19 vaccination, although it was not an objective of the study, the rate of COVID-19 infection in our sample is very low because it occurred before the arrival and dissemination Page 13 of 23 J o u r n a l P r e -p r o o f of the omicron variant in our area. However, the strengths of the study are that the survey was conducted by physicians outside the IBD unit to avoid interfering with its development and that it reflects the real vaccination rate by reviewing the vaccination schedule of each patient. Future studies will allow us to test the efficacy of the vaccination strategy for our IBD patients, including immunosuppressed patients, to ensure its indication and to provide the necessary information and confidence to patients. COVID vaccination strategy in Spain. Ministry of Health. Government of Spain SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multiinstitutional Research Network in the United States COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project Acceptability of Vaccines Against Preventable Infections Including Coronavirus Disease 2019 Among Patients With Rheumatic Disease Optimizing Immunization Strategies in Patients with IBD -Have you ever had COVID 19 infection? Yes/No 2-Have you been vaccinated against COVID? Yes / No -If you have not been vaccinated *The information provided by the survey call (which encourages you to get vaccinated) makes you change your mind: yes/no *Consult with your regular doctor or Unit nurse: yes/no Providing information about the vaccine and its side effects: yes/no *Provide data on the adverse effects of the vaccine: yes/no *Others: 3-If you have been vaccinated, did the health center give you an appointment for the vaccine or did you make the appointment yourself? You were called / Did you make the appointment? 4-In deciding to get vaccinated Diarrhea/ Others: 8-Would you say that your disease was made worse by the vaccination: Yes